Synthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case
NCT06794281 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500
Last updated 2025-03-12
Summary
Haematological diseases (HDs) are a large group of disorders resulting from quantitative or qualitative abnormalities of blood cells, lymphoid organs and coagulation factors. Despite most of them (\~74%) are rare, the overall number of HD affected patients worldwide is important, placing a considerable economic burden on healthcare systems and societies. Despite the existence of several collaborative research groups at national and EU level, current clinical approaches are often ineffective, particularly for rarest conditions, due to the relatively low number of patients per disease and the high number of unconnected clinical entities.
SYNTHEMA aims to establish a cross-border data hub where to develop and validate innovative AI-based techniques for clinical data anonymisation and synthetic data generation (SDG), to tackle the scarcity and fragmentation of data and widen the basis for GDPR-compliant research in rare hematological disorders (RHD). The project will focus on one representative RHD use case: sickle-cell disease (SCD).
Conditions
Interventions
- OTHER
-
Generate synthetic multimodal (clinical, omics and imaging) data for rare haematological diseases with a validated clinical result
O1. Provide novel methods and capabilities to generate synthetic multimodal clinical, omics and imaging data for SCD with a validated clinical result. O2. Develop de-identification, minimisation and anonymisation pipelines, including automatic assessment of privacy levels, at the service of clinical research and care. O3. Consolidate and scale-up the use of FL applications, SMPC and DP solutions for privacy-preserving local algorithm training and global model aggregation. O4. Ensure ethical and GDPR compliance in anonymised and synthetic data-driven research in RHDs. O5. Ensure wide uptake and scalability of the developed methodologies and tools through effective stakeholder engagement, dissemination and open science practices.
Sponsors & Collaborators
-
Universidad Politecnica de Madrid
collaborator OTHER -
Datawizard SRL
collaborator UNKNOWN -
University of Southampton
collaborator OTHER -
Humanitas Mirasole SpA
collaborator OTHER -
Charite University, Berlin, Germany
collaborator OTHER -
Universita degli Studi di Padova
collaborator UNKNOWN -
Assistance Publique - Hôpitaux de Paris
collaborator OTHER -
Vicomtech
collaborator UNKNOWN -
GLSMED Learning Health S.A.
collaborator OTHER -
UMC Utrecht
collaborator OTHER -
Intrasoft
collaborator UNKNOWN -
Hospital Universitari Vall d'Hebron Research Institute
lead OTHER
Eligibility
- Min Age
- 1 Year
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-11-01
- Primary Completion
- 2026-11-30
- Completion
- 2026-11-30
Countries
- Italy
- Netherlands
- Spain
Study Locations
More Related Trials
-
ERN-EuroBloodNet Registry on Patients With Rare Red Blood Cell Defects and COVID-19
NCT06831799 ·Status: COMPLETED
-
Cooperative Assessment of Late Effects for SCD Curative Therapies
NCT05153967 ·Status: RECRUITING
-
Decision Aid for Therapeutic Options In Sickle Cell Disease
NCT02326597 ·Status: COMPLETED ·Phase: NA
-
Assessment of Algorithm-Based Hydroxyurea Dosing on Fetal Hemoglobin Response, Acute Complications, and Organ Function in People With Sickle Cell Disease
NCT02225132 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
NCT06363760 ·Status: ENROLLING_BY_INVITATION
-
Study of a Red Blood Cell Deformability Parameter in Patients With Sickle Cell Disease
NCT03977532 ·Status: COMPLETED ·Phase: NA
-
Sickle Cell Disease: Targeting Alloantibody Formation Reduction; Risk Factors, and Genetics
NCT03288012 ·Status: UNKNOWN
-
Hydroxyurea in the Treatment of Sickle Cell Disease
NCT02709681 ·Status: COMPLETED
-
Future of Spermatogenesis in Men With Sickle Cell Disease Medically Treated
NCT01609192 ·Status: COMPLETED ·Phase: PHASE4
-
Using Patient-Centered Guidelines in a Technology Platform to Improve Health Care in Adults With Sickle Cell Disease
NCT03629678 ·Status: COMPLETED ·Phase: NA
-
SCRIPT: Sickle Cell Risk in Pregnancy Tool
NCT06529042 ·Status: ENROLLING_BY_INVITATION
-
Study of Vidaza (Azacitidine) Versus Support Treatment in Patients With Low Risk Myelodysplastic Syndrome (Low and Intermediate-1 IPSS) Without the 5q Deletion and Transfusion Dependent Anaemia
NCT01338337 ·Status: COMPLETED ·Phase: PHASE2
-
Long-term Comparative Cerebrovascular Outcome After Transplantation vs Standard Care in Sickle Cell Anemia
NCT05053932 ·Status: UNKNOWN
-
Genomic Screening for Hereditary Erythrocytosis and Related Diseases
NCT03263364 ·Status: UNKNOWN
-
RH Genotype Matched RBC Transfusions
NCT04156893 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Venous Thrombosis Biomarkers in Sickle Cell Disease and Sickle Cell Trait
NCT04349189 ·Status: COMPLETED
-
The Influence of micro-and Macro Vascular Dysfunction on Clinical Severity in Adults With Sickle Cell Anemia (SS) and Sickle Cell Hemoglobin C Disease (SC)
NCT07277023 ·Status: COMPLETED ·Phase: NA
-
Hypoxic Red Blood Cells in Sickle Cell Anemia
NCT06743113 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Evaluation of Spectra Optia Red Blood Cell Exchange in Sickle Cell Patients
NCT01736657 ·Status: COMPLETED ·Phase: NA
-
Inflammatory Response to Hydroxyurea Therapy in Sickle Cell Disease
NCT00784082 ·Status: COMPLETED
-
Induction of Stable Chimerism for Sickle Cell Anemia
NCT00029393 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies
NCT00777231 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Integrative Diagnosis for SCD and Other RADs
NCT07206095 ·Status: RECRUITING
-
The Genetics and Functional Basis of Inherited Platelet, White Blood Cell, Red Blood Cell, and Blood Clotting Disorders.
NCT00230165 ·Status: RECRUITING
-
Evaluation of the AMICUS RBCx System in Sickle Cell Patients
NCT02372877 ·Status: COMPLETED ·Phase: NA